StreetInsider.com News Articles

Antengene licenses ATG-106 to K2 Therapeutics for up to $980M

Sun, 21 Jun 2026 20:30:20 -0400

Antengene Corporation Limited (SEHK: 6996.HK) announced it has entered into an exclusive license agreement with K2 Therapeutics, granting the company global rights, excluding Greater China, to develop and commercialize ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) being developed for solid tumors including ovarian and renal cancers.

Under the license agreement, Antengene will receive upfront and near-term considerations of approximately $20 million, consisting of cash and a minority equity stake in a newly established asset company and subsidiary of K2 Therapeutics, subject to certain conditions. Antengene is also eligible to receive up to $960.5 million in developmental, regulatory,

Antengene licenses ATG-106 to K2 Therapeutics for up to $980M

Sun, 21 Jun 2026 20:30:20 -0400

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

Sun, 21 Jun 2026 20:30:00 -0400

ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors
K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China
Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones
K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China
The deal underscores AnTenGager^® platform's differentiated capabilities in

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Tue, 09 Jun 2026 21:00:00 -0400

SHANGHAI and HONG KONG, June 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody, for the treatment of B cell related autoimmune diseases.

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Tue, 09 Jun 2026 21:00:00 -0400

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Tue, 09 Jun 2026 21:00:00 -0400

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Tue, 09 Jun 2026 21:00:00 -0400

Antengene presents preclinical data for ATG-207 autoimmune drug candidate

Sun, 07 Jun 2026 20:00:16 -0400

Antengene Corporation Limited (SEHK: 6996) presented preclinical data for its experimental autoimmune disease treatment ATG-207 at the European Congress of Rheumatology held June 3-6 in London, according to a company statement.

The biotech company reported that ATG-207, described as a masked CD3-TGF-β bifunctional fusion protein, demonstrated activity in laboratory studies designed to evaluate its potential for treating autoimmune conditions. The compound showed preferential binding to TGFβRIII receptors and reduced T cell receptor expression on primary T cells.

In studies using cells from healthy donors and systemic lupus erythematosus patients, ATG-207 induced regulatory T cell activity as measured by FOXP3 expression. The company

Antengene presents preclinical data for ATG-207 autoimmune drug candidate

Sun, 07 Jun 2026 20:00:16 -0400

In studies using cells from healthy donors and systemic lupus erythematosus patients, ATG-207 induced regulatory T cell activity as measured by FOXP3 expression. The company

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

Sun, 07 Jun 2026 20:00:00 -0400

SHANGHAI and HONG KONG, June 7, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it has presented the first preclinical data on ATG-207, α masked and TGFβRIII-biased CD3-TGF-β bifunctional fusion protein in a poster presentation at the 2026 European Congress of Rheumatology (EULAR 2026), held from June 3 to 6 at Excel London in the

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

Sun, 07 Jun 2026 20:00:00 -0400

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

Sun, 07 Jun 2026 20:00:00 -0400

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

Sun, 07 Jun 2026 20:00:00 -0400

Antengene to present preclinical data on ATG-207 autoimmune drug at EULAR

Wed, 03 Jun 2026 00:00:17 -0400

Antengene Corporation Limited (SEHK: 6996) announced it will present preclinical data on ATG-207, an experimental autoimmune disease treatment, at the European Congress of Rheumatology taking place June 3-6 in London.

ATG-207 is a bifunctional fusion protein designed to target T cell-mediated autoimmune diseases. The compound represents Antengene's first disclosed program from its autoimmune disease research efforts.

According to the company's press release, preclinical studies showed ATG-207 demonstrated preferential binding to TGFβRIII, downregulated T cell receptor expression, and induced regulatory T cells in laboratory tests. The compound showed therapeutic efficacy through a mouse surrogate molecule in an experimental autoimmune encephalomyelitis model.

The studies indicated

Antengene to present preclinical data on ATG-207 autoimmune drug at EULAR

Wed, 03 Jun 2026 00:00:17 -0400

The studies indicated

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

Wed, 03 Jun 2026 00:00:00 -0400

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will present the first preclinical data on ATG-207 (αCD3-TGF-β bifunctional fusion protein) in a poster presentation at the 2026 European Congress of Rheumatology (EULAR 2026), taking place from June 3 to 6 at Excel London in the

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

Wed, 03 Jun 2026 00:00:00 -0400

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

Wed, 03 Jun 2026 00:00:00 -0400

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

Wed, 03 Jun 2026 00:00:00 -0400

Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

Wed, 27 May 2026 20:00:00 -0400

SHANGHAI and HONG KONG, May 27, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that following review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), the company has received CDE endorsement to conduct the pivotal Phase III CLINCH-3 study of ATG-022, a Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), for the treatment of CLDN18.2+

Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

Wed, 27 May 2026 20:00:00 -0400

Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

Wed, 27 May 2026 20:00:00 -0400